- Home
- SPPP vs ACRS Comparison
SPPP vs ACRS Comparison
Compare SPPP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- ACRS
- Stock Information
- Founded
- SPPP 2011
- ACRS 2012
- Country
- SPPP Canada
- ACRS United States
- Employees
- SPPP N/A
- ACRS N/A
- Industry
- SPPP
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- ACRS Health Care
- Exchange
- SPPP NYSE
- ACRS Nasdaq
- Market Cap
- SPPP 172.2M
- ACRS 165.7M
- IPO Year
- SPPP N/A
- ACRS 2015
- Fundamental
- Price
- SPPP $11.65
- ACRS $1.42
- Analyst Decision
- SPPP
- ACRS Strong Buy
- Analyst Count
- SPPP 0
- ACRS 8
- Target Price
- SPPP N/A
- ACRS $9.71
- AVG Volume (30 Days)
- SPPP 183.3K
- ACRS 1.3M
- Earning Date
- SPPP 01-01-0001
- ACRS 08-06-2025
- Dividend Yield
- SPPP N/A
- ACRS N/A
- EPS Growth
- SPPP N/A
- ACRS N/A
- EPS
- SPPP N/A
- ACRS N/A
- Revenue
- SPPP N/A
- ACRS $17,777,000.00
- Revenue This Year
- SPPP N/A
- ACRS N/A
- Revenue Next Year
- SPPP N/A
- ACRS $11.77
- P/E Ratio
- SPPP N/A
- ACRS N/A
- Revenue Growth
- SPPP N/A
- ACRS N/A
- 52 Week Low
- SPPP $8.55
- ACRS $1.05
- 52 Week High
- SPPP $11.39
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- SPPP 73.98
- ACRS 57.34
- Support Level
- SPPP $11.36
- ACRS $1.34
- Resistance Level
- SPPP $11.58
- ACRS $1.66
- Average True Range (ATR)
- SPPP 0.27
- ACRS 0.09
- MACD
- SPPP 0.03
- ACRS 0.01
- Stochastic Oscillator
- SPPP 89.54
- ACRS 69.55
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.